Read More Pharma Industry News Chimeric Therapeutics announces breakthrough AML response with CHM CORE-NK in Phase 1B trial Chimeric Therapeutics has reported a significant milestone in its ongoing clinical trials, wherein a patient diagnosed with Acute… byPallavi MadhirajuOctober 7, 2024